HANK & LIN'S GROUP
The past is prologue and the future is scintillating
🌹AD显像药物[18F] D3FSP ([18F] P16-129) Vs [18F]AV-45
1. Zha Z, Ploessl K, Choi SR, Alexoff D, Kung HF*. Preclinical evaluation of [18F] D3FSP, deuterated AV-45, for imaging of β-amyloid in the brain. Nuclear medicine and biology. 2021 Jan 1;92:97-106
2.张利芳 等：“An Improved Preparation of [18F]AV-45 by Simplified Solid-Phase Extraction Purification.” Journal of labelled compounds & radiopharmaceuticals. 63.3 (2020): 108–118.
3.刘亚静 等，"Optimization of automated radiosynthesis of [18F] AV-45: a new PET imaging agent for Alzheimer's disease." Nuclear medicine and biology 37, no. 8 (2010): 917-925.
4.Wong, Dean, Hiroto Kuwabara, Kelly Kitzmiller, Ayon Nandi, Zabecca Brinson, Noble George, David Alexoff et al. "Comparison of [18F] D3FSP ([18F] P16-129) and [18F] AV45 in Alzheimer’s Disease."Journal of Nuclear Medicine 60, no. supplement 1 (2019): 1457-1457
5.姚新月, 赵睿玥, 查智豪, Seok Choi, Karl Ploessl, David Alexoff, Lin Zhu, and Hank Kung. "Optimization of solid phase extraction (SPE) in preparation of D3-[18F] FSP: A new PET imaging agent for mapping Aβ plaques." Journal of Nuclear Medicine 60, no. supplement 1 (2019): 485-485.
6.Zha, Zhihao, Karl Ploessl, David Alexoff, Seok Choi, Zehui Wu, Lin Zhu, and Hank Kung. "[18F] D3FSP ([18F] D3AV-45) as a PET imaging agent for Abeta plaques in the brain." Journal of Nuclear Medicine 59, no. supplement 1 (2018): 1031-1031.
🌻VMAT2靶向显像剂[18F]D6-FP-DTBZ Vs [18F]AV-133
1.赵睿玥, 查智豪, 姚新月, Karl Ploessl, Seok Rye Choi, Futao Liu, Lin Zhu, and Hank F. Kung. "VMAT2 imaging agent, D6-[18F] FP-(+)-DTBZ: Improved radiosynthesis, purification by solid-phase extraction and characterization."Nuclear medicine and biology 72 (2019): 26-35.
2.刘福涛, Seok Rye Choi, 查智豪, Karl Ploessl, Lin Zhu, and Hank F. Kung. "Deuterated 18F-9-O-hexadeutero-3-fluoropropoxyl-(+)-dihydrotetrabenazine (D6-FP-(+)-DTBZ): A vesicular monoamine transporter 2 (VMAT2) imaging agent."Nuclear medicine and biology 57 (2018): 42-49.
3.Zhu, Lin, Hongwen Qiao, Brian P. Lieberman, Jingxiao Wu, Yajing Liu, Zhongyun Pan, Karl Ploessl, Seok Rye Choi, Piu Chan, and Hank F. Kung. "Imaging of VMAT2 binding sites in the brain by 18F-AV-133: The effect of a pseudo-carrier."Nuclear medicine and biology 39, no. 7 (2012): 897-904.
4.Zhu, Lin, 刘亚静, Karl Plössl, Brian Lieberman, Jingying Liu, and Hank F. Kung. "An improved radiosynthesis of [18F] AV-133: a PET imaging agent for vesicular monoamine transporter 2."Nuclear medicine and biology 37, no. 2 (2010): 133-141.
5. Zhao, R., Chen, J., Ye, T.et al.First-in-human study of D6-[18F]FP-(+)-DTBZ, a novel VMAT2 tracer: whole-body biodistribution and brain PET comparison with [18F]FP-(+)-DTBZ (AV-133). EJNMMI radiopharm. chem.9, 71 (2024). https://doi.org/10.1186/s41181-024-00301-y
⚜️五羟色胺转运体（SERT）靶向显像药物:[18F]FPBM derivatives
1.张岩, 刘福涛, Hao Xiao, Xinyue Yao, Genxun Li, Seok Rye Choi, Karl Ploessl, Zhihao Zha, Lin Zhu, and Hank F. Kung. "Fluorine-18 labeled diphenyl sulfide derivatives for imaging serotonin transporter (SERT) in the brain." Nuclear medicine and biology 66 (2018): 1-9.
2.刘福涛, Lin Zhu, Seok Rye Choi, Karl Plössl, Zhihao Zha, and Hank F. Kung. "Deuterium‐substituted 2‐(2′‐((dimethylamino) methyl)‐4′‐[18F](fluoropropoxy) phenylthio) benzenamine as a serotonin transporter imaging agent." Journal of Labelled Compounds and Radiopharmaceuticals 61, no. 8 (2018): 576-58.
3.Qiao, Hongwen, Yan Zhang, Zehui Wu, Lin Zhu, Seok Rye Choi, Karl Ploessl, and Hank F. Kung. "One-step preparation of [18F] FPBM for PET imaging of serotonin transporter (SERT) in the brain."Nuclear medicine and biology 43, no. 8 (2016): 470-477.
4.Zhu L, Li G., Choi S., et al., An improved preparation of [18F]FPBM: A potential serotonin transporter (SERT) imaging agent. Nucl Med Biol. 2013;40(8):974-979.
5.Hongwen Qiao, Yan Zhang, Zehui Wu, Lin Zhu, Karl Ploessl and Hank Kung.One-Step Preparation of [18F]FPBM for PET Imaging of Serotonin Transporter (SERT) in the Brain.Journal of Nuclear Medicine May 2016, 57 (supplement 2) 1807
🍇[18F]谷氨酰胺代谢显像剂:[18F]-(2S,4R)4-Fluoroglutamine
1.Zhu L , Ploessl K , Zhou R , et al. Metabolic Imaging of Glutamine in Cancer[J]. Journal of Nuclear Medicine, 2017, 58(4), 533-537.
2.张岩, 张利芳, Jianhua Yang, Zehui Wu, Karl Ploessl, Zhihao Zha, Fei Liu et al. "Initial experience in synthesis of (2 S, 4 R)‐4‐[18F] fluoroglutamine for clinical application." Journal of Labelled Compounds and Radiopharmaceuticals 62, no. 5 (2019): 209-214.
3.张岩, 张利芳, Zehui Wu, Jianhua Yang, Karl Ploessl, Zhihao Zha, Liu Fei et al. "Automated radiosynthesis of (2S, 4R)-4-[F-18] fluoroglutamine for clinical application." In JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, vol. 62, pp. S322-S323. 111 RIVER ST, HOBOKEN 07030-5774, NJ USA: WILEY, 2019.
4.Qu, Wenchao, Zhihao Zha, Karl Ploessl, Brian P. Lieberman, Lin Zhu, David R. Wise, Craig B. Thompson, and Hank F. Kung. "Synthesis of optically pure 4-fluoro-glutamines as potential metabolic imaging agents for tumors." Journal of the American Chemical Society 133, no. 4 (2011): 1122-1133.
5.Venneti, Sriram, et al. "Glutamine-based PET imaging facilitates enhanced metabolic evaluation of gliomas in vivo." Science translational medicine 7.274 (2015): 274ra17-274ra17.
6.Xu, Xiaoxia, Hua Zhu, Fei Liu, Yan Zhang, Jianhua Yang, Lifang Zhang, Qing Xie et al. "Dynamic PET/CT imaging of 18F-(2 S, 4 R) 4-fluoroglutamine in healthy volunteers and oncological patients." European Journal of Nuclear Medicine and Molecular Imaging (2020): 1-13.
7.Xu, Xiaoxia, Zhi Yang, and Hank Kung. "18F-FGln PET/CT guided surgical biopsy and resection in patient with brain tumors." Journal of Nuclear Medicine 61.supplement 1 (2020): 410-410.
🌞新的显像探针
1.FAPI靶向探针
2.双靶向探针
3.Tau 显像探针
